Application status and thinking of minimal residual disease-monitoring in multiple my-eloma after stem cell transplantation
10.3969/j.issn.1000-8179.2018.11.259
- VernacularTitle:微小残留病检测在多发性骨髓瘤移植后患者中的应用现状与思考
- Author:
Yanjie XU
1
;
Yizhuo ZHANG
Author Information
1. 天津医科大学肿瘤医院血液肿瘤科
- Keywords:
multiple myeloma;
transplantation;
minimal residual disease;
flow cytometry;
next generation sequencing
- From:
Chinese Journal of Clinical Oncology
2018;45(11):548-552
- CountryChina
- Language:Chinese
-
Abstract:
The efficacy of multiple myeloma (MM) treatments, particularly novel medicines and transplantation, has improved rapidly in the last ten years, with increasing rates of progression-free survival (PFS) and overall survival (OS). However, complete response (CR) is not enough as prognostic indicator guidance. Therefore, methods have been developed to monitor minimal residual disease (MRD), such as serum free light chain (sFLC), flow cytometry, polymerase chain reaction (PCR), next generation sequencing (NGS), and PET-CT. This article reviewed the current situation of the application of those methods in MM patients after stem cell transplantation.
